

Kuittinen T, Rovio P, Luukkaala T, Laurila M, Grénman S, Kallioniemi A, Mäenpää J. 2020. Paclitaxel, carboplatin and 1,25-D3 inhibit proliferation of ovarian cancer cells in vitro. *Anticancer Research*. 40(6):3129-3138. <https://doi.org/10.2196/10.21873/anticancer.14294>

Kohvakka A, Sattari M, Shcherban A, Annala M, Urbanucci A, Kesseli J, Tammela TLJ, Kivinummi K, Latonen L, Nykter M, Visakorpi T. 2020. AR and ERG drive the expression of prostate cancer specific long noncoding RNAs. *Oncogene*. 39:5241–5251. <https://doi.org/10.1038/s41388-020-1365-6>

Lehti M, Valkeinen H, Sipilä S, Perhonen M, Rottensteiner M, Pullinen T, Pietiläinen R, Nyman K, Vehkaoja A, Kainulainen H, Kujala UM. 2020. Effects of aerobic and strength training on aerobic capacity, muscle strength, and gene expression of lymphomonocytes in patients with stable CAD. *American Journal of Translational Research*. 12(8):4582-4593.

Nissinen SI, Roine A, Hokkinen L, Karjalainen M, Venäläinen M, Helminen H, Niemi R, Lehtimäki T, Rantanen T, Oksala N. 2019. Detection of Pancreatic Cancer by Urine Volatile Organic Compound Analysis. *Anticancer Research*. 39(1):73-79. <https://doi.org/10.21873/anticancer.13081>

Nurmi A, Muranen TA, Pelttari LM, Kiiski JI, Heikkinen T, Lehto S, Kallioniemi A, Schleutker J, Bützow R, Blomqvist C, Aittomäki K, Nevanlinna H. 2019. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients. *International Journal of Cancer*. <https://doi.org/10.1002/ijc.32309>

Venäläinen MK, Roine AN, Häkkinen MR, Vepsäläinen JJ, Kumpulainen PS, Kiviniemi MS, Lehtimäki T, Oksala NK, Rantanen TK. 2018. Altered polyamine profiles in colorectal cancer. *Anticancer Research*. 38(6):3601-3607. <https://doi.org/10.21873/anticancer.12634>

Vuorinen EM, Rajala NK, Ihalainen TO, Kallioniemi A. 2018. Depletion of nuclear import protein karyopherin alpha 7 (KPNA7) induces mitotic defects and deformation of nuclei in cancer cells. *BMC Cancer*. 18(1). <https://doi.org/10.1186/s12885-018-4261-5>

Granberg KJ, Annala M, Lehtinen B, Kesseli J, Haapasalo J, Ruusuvoori P, Yli-Harja O, Visakorpi T, Haapasalo H, Nykter M, Zhang W. 2017. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas. *Neuro-Oncology*. 19(9):1206-1216. <https://doi.org/10.1093/neuonc/nox028>

Lehtinen B, Raita A, Kesseli J, Annala M, Nordfors K, Yli-Harja O, Zhang W, Visakorpi T, Nykter M, Haapasalo H, Granberg KJ. 2017. Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas. *BMC Cancer*. 17(1). <https://doi.org/10.1186/s12885-017-3274-9>

Wu X, Bhattarai A, Korkola P, Pertovaara H, Eskola H, Kellokumpu-Lehtinen PL. 2017. The Association Between Liver and Tumor [¹⁸F]FDG Uptake in Patients with Diffuse Large B Cell Lymphoma During Chemotherapy. *Molecular Imaging and Biology*. 19(5):787–794. <https://doi.org/10.1007/s11307-017-1044-3>

Kuusela J, Kim J, Räsänen E, Aalto-Setälä K. 2016. The Effects of Pharmacological Compounds on Beat Rate Variations in Human Long QT-Syndrome Cardiomyocytes. *Stem Cell Reviews and Reports*. 12(6):698–707. <https://doi.org/10.1007/s12015-016-9686-0>

Manzini S, Viiri LE, Marttila S, Aalto-Setälä K. 2015. A Comparative View on Easy to Deploy non-Integrating Methods for Patient-Specific iPSC Production. *Stem Cell Reviews and Reports*. 11(6):900-908. <https://doi.org/10.1007/s12015-015-9619-3>

Friis S, Kesminiene A, Espina C, Auvinen A, Straif K, Schüz J. 2015. European Code against Cancer 4th Edition: Medical exposures, including hormone therapy, and cancer. *CANCER EPIDEMIOLOGY*. 39:S107-S119. <https://doi.org/10.1016/j.canep.2015.08.003>

McCull N, Auvinen A, Kesminiene A, Espina C, Erdmann F, de Vries E, Greinert R, Harrison J, Schüz J. 2015. European Code against Cancer 4th Edition: Ionising and non-ionising radiation and cancer. *CANCER EPIDEMIOLOGY*. 39:S93-S100. <https://doi.org/10.1016/j.canep.2015.03.016>

Greinert R, de Vries E, Erdmann F, Espina C, Auvinen A, Kesminiene A, Schüz J. 2015. European Code against Cancer 4th Edition: Ultraviolet radiation and cancer. *CANCER EPIDEMIOLOGY*. 39:S75-S83. <https://doi.org/10.1016/j.canep.2014.12.014>

Ylipää A, Kivinummi K, Kohvakka A, Annala M, Latonen L, Scaravilli M, Kartasalo K, Leppänen SP, Karakurt S, Seppälä J, Yli-Harja O, Tammela TLJ, Zhang W, Visakorpi T, Nykter M. 2015. Transcriptome sequencing reveals PCAT5 as a Novel ERG-Regulated long Noncoding RNA in prostate cancer. *Cancer Research*. 75(19):4026-4031. <https://doi.org/10.1158/0008-5472.CAN-15-0217>

Hietanen T, Pitkänen M, Kapanen M, Kellokumpu-Lehtinen PL. 2015. Effects of single and fractionated irradiation on natural killer cell populations: Radiobiological characteristics of viability and cytotoxicity in vitro. *Anticancer Research*. 35(10):5193-5200.

Pashayan N, Pharoah PDP, Schleutker J, Talala K, Tammela TLJ, Määttä L, Harrington P, Tyrer J, Eeles R, Duffy SW, Auvinen A. 2015. Reducing overdiagnosis by polygenic risk-stratified screening: Findings from the Finnish section of the ERSPC. *British Journal of Cancer*. 113(7):1086-1093. <https://doi.org/10.1038/bjc.2015.289>

Umbehre MH, Gurel B, Murtola TJ, Sutcliffe S, Peskoe SB, Tangen CM, Goodman PJ, Thompson IM, Lippman SM, Lucia MS, Parnes HL, Drake CG, Nelson WG, De Marzo AM, Platz EA. 2015. Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ngml⁻¹, normal DRE and negative for prostate cancer. *PROSTATE CANCER AND PROSTATIC DISEASES*. 18(3):264-269. <https://doi.org/10.1038/pcan.2015.19>

Kaapu KJ, Ahti J, Tammela TLJ, Auvinen A, Murtola TJ. 2015. Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population-based case-control study. *International Journal of Cancer*. 137(5):1187-1195. <https://doi.org/10.1002/ijc.29470>

Rane JK, Ylipää A, Adamson R, Mann VM, Simms MS, Collins AT, Visakorpi T, Nykter M, Maitland NJ. 2015. Construction of therapeutically relevant human prostate epithelial fate map by utilising miRNA and mRNA microarray expression data. *British Journal of Cancer*. 113(4):611-615. <https://doi.org/10.1038/bjc.2015.262>

Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Mönkkönen J, Kellokumpu-Lehtinen PL, Lauttia S, Tynninen O, Joensuu H, Heymann D, Määttä JA. 2015. Human breast cancer cells educate macrophages toward the M2 activation status. *BREAST CANCER RESEARCH*. 17(1). <https://doi.org/10.1186/s13058-015-0621-0>

Kapanen M, Laaksomaa M, Tulijoki T, Kellokumpu-Lehtinen PL, Hyödynmaa S. 2015. Effects of remedies made in patient setup process on residual setup errors and margins in head and neck cancer radiotherapy based on 2D image guidance. *Reports of Practical Oncology and Radiotherapy*. 20(4):292-298. <https://doi.org/10.1016/j.rpor.2015.03.002>

Zoni E, Van Der Horst G, Van De Merbel AF, Chen L, Rane JK, Pelger RCM, Collins AT, Visakorpi T, Snaar-Jagalska BE, Maitland NJ, Van Der Pluijm G. 2015. MIR-25 modulates invasiveness and dissemination of human prostate cancer cells via regulation of α v- and α 6-integrin expression. *Cancer Research*. 75(11):2326-2336. <https://doi.org/10.1158/0008-5472.CAN-14-2155>

Thomsen FB, Brasso K, Christensen IJ, Johansson JE, Angelsen A, Tammela TLJ, Iversen P. 2015. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study. *EUROPEAN JOURNAL OF CANCER*. 51(10):1283-1292. <https://doi.org/10.1016/j.ejca.2015.03.021>

Laitinen VH, Rantapero T, Fischer D, Vuorinen EM, Tammela TLJ, Wahlfors T, Schleutker J. 2015. Fine-mapping the 2q37 and 17q11.2-q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancer. *International Journal of Cancer*. 136(10):2316-2327. <https://doi.org/10.1002/ijc.29276>

Kilpeläinen TP, Tammela TLJ, Malila N, Hakama M, Santti H, Määttä L, Stenman UH, Kujala P, Auvinen A. 2015. The Finnish prostate cancer screening trial: Analyses on the screening failures. *International Journal of Cancer*. 136(10):2437-2443. <https://doi.org/10.1002/ijc.29300>

Veskimäe K, Staff S, Tabaro F, Nykter M, Isola J, Mäenpää J. 2015. Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies. *Genes Chromosomes and Cancer*. 54(5):276-287. <https://doi.org/10.1002/gcc.22241>

Saurus P, Kuusela S, Lehtonen E, Hyvönen ME, Ristola M, Fogarty CL, Tienari J, Lassenius MI, Forsblom C, Lehto M, Saleem MA, Groop PH, Holthöfer H, Lehtonen S. 2015. Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway. *CELL DEATH AND DISEASE*. 6(5). <https://doi.org/10.1038/cddis.2015.125>

Saarimäki L, Tammela TL, Määttänen L, Taari K, Kujala PM, Raitanen J, Auvinen A. 2015. Family history in the Finnish prostate cancer screening trial. *International Journal of Cancer*. 136(9):2172-2177. <https://doi.org/10.1002/ijc.29243>

Schüz J, Espina C, Villain P, Herrero R, Leon ME, Minozzi S, Romieu I, Segnan N, Wardle J, Wiseman M, Belardelli F, Bettcher D, Cavalli F, Galea G, Lenoir G, Martin-Moreno JM, Nicula FA, Olsen JH, Patnick J, Primic-Zakelj M, Puska P, Van Leeuwen FE, Wiestler O, Zatonski W, Guha N, Kralikova E, McNeill A, Peruga A, Anderson A, Berrino F, Boutron-Ruault MC, Cecchini M, Key TJ, Leitzmann M, Norat T, Powers HJ, Scoccianti C, Auvinen A, de Vries E, Erdmann F, Greinert R, Harrison J, Kesminiene A, McColl N, Friis S, Kogevinas M, Saracci R, Straif K, Vainio H, Almonte M, Anttila A, De Vuyst H, Dillner J, Franceschi S, Gonzalez P, Hall A, Park JY, Armaroli P, Atkin W, Dean PB, de Koning H, Dillner L, Kuipers E, Lansdorp-Vogelaar I, Paci E, Regula J, Suonio E, Törnberg S, Wood LF, Gaudin N, Frie KG, Terrasse V, Winstanley K, Bellisario C, Biagioli E, Cinquini M, Gianola S, Lorenzo MG, von Karsa L, Lignini T. 2015. European code against cancer 4th edition: 12 ways to reduce your cancer risk. *CANCER EPIDEMIOLOGY*. 39:S1-S10. <https://doi.org/10.1016/j.canep.2015.05.009>

Tuohinen SS, Skyttä T, Virtanen V, Luukkaala T, Kellokumpu-Lehtinen PL, Raatikainen P. 2015. Early effects of adjuvant breast cancer radiotherapy on right ventricular systolic and diastolic function. *Anticancer Research*. 35(4):2141-2147.

Skyttä T, Tuohinen S, Virtanen V, Raatikainen P, Kellokumpu-Lehtinen PL. 2015. The concurrent use of aromatase inhibitors and radiotherapy induces echocardiographic changes in patients with breast cancer. *Anticancer Research*. 35(3):1559-1566.

Virman JP, Bono P, Luukkaala T, Sunela K, Kujala P, Kellokumpu-Lehtinen PL. 2015. VEGFR3 and CD31 as prognostic factors in renal cell cancer. *Anticancer Research*. 35(2):921-927.

Emmert-Streib F, Zhang SD, Hamilton P. 2015. Computational cancer biology: education is a natural key to many locks. *BMC Cancer*. 15(1). <https://doi.org/10.1186/s12885-014-1002-2>

Heijnsdijk EAM, De Carvalho TMD, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Tammela TLJ, Recker F, Denis L, Carlsson SV, Wever EM, Bangma CH, Schröder FH, Roobol MJ, Hugosson J, De Koning HJ. 2015. Cost-effectiveness of prostate cancer screening: A simulation study based on ERSPC data. *JOURNAL OF THE NATIONAL CANCER INSTITUTE*. 107(1). <https://doi.org/10.1093/jnci/dju366>

Laaksomaa M, Kapanen M, Skyttä T, Peltola S, Hyödynmaa S, Kellokumpu-Lehtinen PL. 2014. Estimation of optimal matching position for orthogonal kV setup images and minimal setup margins in radiotherapy of whole breast and lymph node areas. *Reports of Practical Oncology and Radiotherapy*. 19(6):369-375. <https://doi.org/10.1016/j.rpor.2014.05.001>

Virman JP, Soini Y, Kujala P, Luukkaala T, Salminen T, Sunela K, Kellokumpu-Lehtinen PL. 2014. Claudins as prognostic factors for renal cell cancer. *Anticancer Research*. 34(8):4181-4188.

Carlsson S, Roobol MJ, Schröder FH, Hugosson J, Auvinen A. 2014. RE: Prostate-specific antigen screening trials and prostate cancer deaths: The androgen deprivation connection. *JOURNAL OF THE NATIONAL CANCER INSTITUTE*. 106(5). <https://doi.org/10.1093/jnci/dju079>

Mäenpää J, Puistola U, Riska H, Sintonen H, Saarni O, Juvonen E, Kellokumpu-Lehtinen PL. 2014. Impact of epoetin-beta on anemia and health-related quality of life in cancer patients: A prospective observational study using the generic 15D instrument. *Anticancer Research*. 34(5):2325-2330.

Auvinen A, Seppä K, Pasanen K, Kurttio P, Patama T, Pukkala E, Heinävaara S, Arvela H, Verkasalo P, Hakulinen T. 2014. Chernobyl fallout and cancer incidence in Finland 1988-2007. *International Journal of Cancer*. 134(9):2253-2263. <https://doi.org/10.1002/ijc.28554>

Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, Thorsen K, Ostensfeld MS, Wild PJ, Arsov C, Goering W, Visakorpi T, Egevad L, Lindberg J, Grönberg H, Høyer S, Borre M, Orntoft TF, Sørensen KD. 2014. Hypermethylation of the GABRE miR-452/miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. *Clinical Cancer Research*. 20(8):2169-2181. <https://doi.org/10.1158/1078-0432.CCR-13-2642>

Penttinen H, Rautalin M, Roine R, Jahkola T, Kellokumpu-Lehtinen PL, Huovinen R, Kautiainen H, Järvenpää S, Hakamies-Blomqvist L, Blomqvist C, Saarto T. 2014. Quality of life of recently treated patients with breast cancer. *Anticancer Research*. 34(3):1201-1206.

Schrecengost RS, Dean JL, Goodwin JF, Schiewer MJ, Urban MW, Stanek TJ, Sussman RT, Hicks JL, Birbe RC, Draganova-Tacheva RA, Visakorpi T, DeMarzo AM, McMahon SB, Knudsen KE. 2014. USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. *Cancer Research*. 74(1):272-286. <https://doi.org/10.1158/0008-5472.CAN-13-1954>

Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, De Reijke TM, Robson CN, De Santis M, Seruga B, De Wit R. 2014. Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. *EUROPEAN JOURNAL OF CANCER*. 50(9):1617-1627. <https://doi.org/10.1016/j.ejca.2014.03.010>

Traylor M, Mäkelä KM, Kilarski LL, Holliday EG, Devan WJ, Nalls MA, Wiggins KL, Zhao W, Cheng YC, Achterberg S, Malik R, Sudlow C, Bevan S, Raitoharju E, Oksala N, Thijs V, Lemmens R, Lindgren A, Slowik A, Maguire JM, Walters M, Algra A, Sharma P, Attia JR, Boncoraglio GB, Rothwell PM, de Bakker PIW, Bis JC, Saleheen D, Kittner SJ, Mitchell BD, Rosand J, Meschia JF, Levi C, Dichgans M, Lehtimäki T, Lewis CM, Markus HS. 2014. A Novel MMP12 Locus Is Associated with Large Artery Atherosclerotic Stroke Using a Genome-Wide Age-at-Onset Informed Approach. *PLOS GENETICS*. 10(7). <https://doi.org/10.1371/journal.pgen.1004469>

Veitonmäki T, Murtola TJ, Määttänen L, Taari K, Stenman UH, Tammela TL, Auvinen A. 2014. Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. *British Journal of Cancer*. 111(7):1421-1431. <https://doi.org/10.1038/bjc.2014.381>

Laurila EM, Kallioniemi A. 2013. The diverse role of miR-31 in regulating cancer associated phenotypes. *Genes Chromosomes and Cancer*. 52(12):1103-1113. <https://doi.org/10.1002/gcc.22107>

Khanna A, Kauko O, Böckelman C, Laine A, Schreck I, Partanen JI, Szwajda A, Bormann S, Bilgen T, Helenius M, Pokharel YR, Pimanda J, Russel MR, Haglund C, Cole KA, Klefström J, Aittokallio T, Weiss C, Ristimäki A, Visakorpi T, Westermarck J. 2013. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells. *Cancer Research*. 73(22):6757-6769. <https://doi.org/10.1158/0008-5472.CAN-13-1002>

Kellokumpu-Lehtinen PL, Tuunanen T, Kautio AL, Lehtinen I, Tanner M. 2013. Bi-weekly paclitaxel and capecitabine as a second- Or third-line treatment for advanced breast cancer: A pilot study. *Anticancer Research*. 33(11):4941-4945.

Kurttio P, Seppä K, Pasanen K, Patama T, Auvinen A, Pukkala E, Heinävaara S, Arvela H, Hakulinen T. 2013. Fallout from the Chernobyl accident and overall cancer incidence in Finland. *CANCER EPIDEMIOLOGY*. 37(5):585-592. <https://doi.org/10.1016/j.canep.2013.05.006>

Nurminen R, Lehtonen R, Auvinen A, Tammela TLJ, Wahlfors T, Schleutker J. 2013. Fine mapping of 11q13.5 identifies regions associated with prostate cancer and prostate cancer death. *EUROPEAN JOURNAL OF CANCER*. 49(15):3335-3343. <https://doi.org/10.1016/j.ejca.2013.06.006>

- Ampuja M, Jokimäki R, Juuti-Uusitalo K, Rodriguez-Martinez A, Alarmo EL, Kallioniemi A. 2013. BMP4 inhibits the proliferation of breast cancer cells and induces an MMP-dependent migratory phenotype in MDA-MB-231 cells in 3D environment. *BMC Cancer*. 13. <https://doi.org/10.1186/1471-2407-13-429>
- Rahu K, Hakulinen T, Smalyte G, Stengrevics A, Auvinen A, Inskip PD, Boice JD, Rahu M. 2013. Site-specific cancer risk in the Baltic cohort of Chernobyl cleanup workers, 1986-2007. *EUROPEAN JOURNAL OF CANCER*. 49(13):2926-2933. <https://doi.org/10.1016/j.ejca.2013.04.014>
- Högnäs G, Hämälistö S, Rilla K, Laine JO, Vilkki V, Murumägi A, Edgren H, Kallioniemi O, Ivaska J. 2013. Aneuploidy facilitates oncogenic transformation via specific genetic alterations, including Twist2 upregulation. *Carcinogenesis*. 34(9):2000-2009. <https://doi.org/10.1093/carcin/bgt171>
- Dixit D, Ghildiyal R, Anto NP, Ghosh S, Sharma V, Sen E. 2013. Guggulsterone sensitizes glioblastoma cells to Sonic hedgehog inhibitor SANT-1 induced apoptosis in a Ras/NFκB dependent manner. *Cancer Letters*. 336(2):347-358. <https://doi.org/10.1016/j.canlet.2013.03.025>
- Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart MJ, Joensuu H, Sotiriou C. 2013. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. *JOURNAL OF THE NATIONAL CANCER INSTITUTE*. 105(13):960-967. <https://doi.org/10.1093/jnci/djt121>
- Liu W, Xie CC, Thomas CY, Kim ST, Lindberg J, Egevad L, Wang Z, Zhang Z, Sun J, Sun J, Koty PP, Kader AK, Cramer SD, Bova GS, Zheng SL, Grönberg H, Isaacs WB, Xu J. 2013. Genetic markers associated with early cancer-specific mortality following prostatectomy. *Cancer*. 119(13):2405-2412. <https://doi.org/10.1002/cncr.27954>
- Kellokumpu-Lehtinen P, Tuunanen T, Asola R, Elomaa L, Heikkinen M, Kokko R, Järvenpää R, Lehtinen I, Maiche A, Kaleva-Kerola J, Huusko M, Möykkynen K, Ala-Luhtala T. 2013. Weekly paclitaxel-An effective treatment for advanced breast cancer. *Anticancer Research*. 33(6):2623-2628.
- Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määtänen L, Stenman UH, Kujala P, Auvinen A. 2013. Prostate cancer mortality in the finnish randomized screening trial. *JOURNAL OF THE NATIONAL CANCER INSTITUTE*. 105(10):719-725. <https://doi.org/10.1093/jnci/djt038>
- Elme A, Utriainen M, Kellokumpu-Lehtinen P, Palva T, Luoto R, Nikander R, Huovinen R, Kautiainen H, Järvenpää S, Penttinen HM, Vehmanen L, Jääskeläinen AS, Ruohola J, Blomqvist C, Saarto T. 2013. Obesity and physical inactivity are related to impaired physical health of breast cancer survivors. *Anticancer Research*. 33(4):1595-1602.
- Bruchmann A, Roller C, Walther TV, Schäfer G, Lehmusvaara S, Visakorpi T, Klocker H, Cato ACB, Maddalo D. 2013. Bcl-2 associated athanogene 5 (Bag5) is overexpressed in prostate cancer and inhibits ER-stress induced apoptosis. *BMC Cancer*. 13. <https://doi.org/10.1186/1471-2407-13-96>
- Veitonmäki T, Tammela TLJ, Auvinen A, Murtola TJ. 2013. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. *EUROPEAN JOURNAL OF CANCER*. 49(4):938-945. <https://doi.org/10.1016/j.ejca.2012.09.030>
- Rauhala HE, Teppo S, Niemelä S, Kallioniemi A. 2013. Silencing of the arp2/3 complex disturbs pancreatic cancer cell migration. *Anticancer Research*. 33(1):45-52.
- Rantanen T, Kauttu T, Åkerla J, Honkanen T, Krogerus L, Salo J, Paavonen T, Oksala N. 2013. CIP2A expression and prognostic role in patients with esophageal adenocarcinoma. *MEDICAL ONCOLOGY*. 30(3). <https://doi.org/10.1007/s12032-013-0684-7>
- Jayakrishnan R, Uutela A, Mathew A, Auvinen A, Mathew PS, Sebastian P. 2013. Smoking cessation intervention in Rural Kerala, India: Findings of a randomised controlled trial. *ASIAN PACIFIC JOURNAL OF CANCER PREVENTION*. 14(11):6797-6802. <https://doi.org/10.7314/APJCP.2013.14.11.6797>

Jayakrishnan R, Mathew A, Uutela A, Auvinen A, Sebastian P. 2013. Multiple approaches and participation rate for a community based smoking cessation intervention trial in rural Kerala, India. *ASIAN PACIFIC JOURNAL OF CANCER PREVENTION*. 14(5):2891-2896. <https://doi.org/10.7314/APJCP.2013.14.5.2891>

Pukkala E, Helminen M, Haldorsen T, Hammar N, Kojo K, Linnertsjö A, Rafnsson V, Tulinius H, Tveten U, Auvinen A. 2012. Cancer incidence among Nordic airline cabin crew. *International Journal of Cancer*. 131(12):2886-2897. <https://doi.org/10.1002/ijc.27551>

Wu GHM, Auvinen A, Määttänen L, Tammela TLJ, Stenman UH, Hakama M, Yen AMF, Chen HH. 2012. Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening. *International Journal of Cancer*. 131(6):1367-1375. <https://doi.org/10.1002/ijc.27340>

Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TLJ, Ke C, Leder BZ, Goessl C. 2012. Sarcopenia during androgen-deprivation therapy for prostate cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 30(26):3271-3276. <https://doi.org/10.1200/JCO.2011.38.8850>

Saarto T, Penttinen HM, Sievänen H, Kellokumpu-Lehtinen PL, Hakamies-Blomqvist L, Nikander R, Huovinen R, Luoto R, Kautiainen H, Järvenpää S, Idman I, Utriainen M, Vehmanen L, Jääskeläinen AS, Elme A, Ruohola J, Palva T, Vertio H, Rautalahti M, Fogelholm M, Blomqvist C, Luoma ML. 2012. Effectiveness of a 12-month exercise program on physical performance and quality of life of breast cancer survivors. *Anticancer Research*. 32(9):3875-3884.

Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Marttila T, Seke M, Taalikka M, Ginman C. 2012. Toxicity in patients receiving adjuvant docetaxel hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: A preplanned safety report of the SPCG-13 trial. *PROSTATE CANCER AND PROSTATIC DISEASES*. 15(3):303-307. <https://doi.org/10.1038/pcan.2012.13>

Egerdie RB, Saad F, Smith MR, Tammela TLJ, Heracek J, Sieber P, Ke C, Leder B, Dansey R, Goessl C. 2012. Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. *PROSTATE CANCER AND PROSTATIC DISEASES*. 15(3):308-312. <https://doi.org/10.1038/pcan.2012.18>

Liu W, Lindberg J, Sui G, Luo J, Egevad L, Li T, Xie C, Wan M, Kim ST, Wang Z, Turner AR, Zhang Z, Feng J, Yan Y, Sun J, Bova GS, Ewing CM, Yan G, Gielzak M, Cramer SD, Vessella RL, Zheng SL, Grönberg H, Isaacs WB, Xu J. 2012. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. *Oncogene*. 31(35):3939-3948. <https://doi.org/10.1038/onc.2011.554>

Högnäs G, Tuomi S, Veltel S, Mattila E, Murumägi A, Edgren H, Kallioniemi O, Ivaska J. 2012. Cytokinesis failure due to derailed integrin traffic induces aneuploidy and oncogenic transformation in vitro and in vivo. *Oncogene*. 31(31):3597-3606. <https://doi.org/10.1038/onc.2011.527>

Inouye M, Ripatti S, Kettunen J, Lyytikäinen LP, Oksala N, Laurila PP, Kangas AJ, Soininen P, Savolainen MJ, Viikari J, Kähönen M, Perola M, Salomaa V, Raitakari O, Lehtimäki T, Taskinen MR, Järvelin MR, Ala-Korpela M, Palotie A, de Bakker PIW. 2012. Novel Loci for Metabolic Networks and Multi-Tissue Expression Studies Reveal Genes for Atherosclerosis. *PLOS GENETICS*. 8(8). <https://doi.org/10.1371/journal.pgen.1002907>

Hervonen P, Tulijoki T, Kellokumpu-Lehtinen P. 2012. No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer. *Anticancer Research*. 32(8):3305-3310.

Martens-Uzunova ES, Jalava SE, Dits NF, Van Leenders GJLH, Møller S, Trapman J, Bangma CH, Litman T, Visakorpi T, Jenster G. 2012. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. *Oncogene*. 31(8):978-991. <https://doi.org/10.1038/onc.2011.304>

Bryant RJ, Pawlowski T, Catto JWF, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T, Hamdy FC. 2012. Changes in circulating microRNA levels associated with prostate cancer. *British Journal of Cancer*. 106(4):768-774. <https://doi.org/10.1038/bjc.2011.595>

Dixit D, Sharma V, Ghosh S, Mehta VS, Sen E. 2012. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNF α)-induced apoptosis through SIRT1 inhibition. *CELL DEATH AND DISEASE*. 3(2). <https://doi.org/10.1038/cddis.2012.10>

Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Pajja O, Helle L, Villman K, Nyandoto P, Nilsson G, Pajunen M, Asola R, Poikonen P, Leinonen M, Kataja V, Bono P, Lindman H. 2012. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: Final analysis of the randomized FinXX trial. *JOURNAL OF CLINICAL ONCOLOGY*. 30(1):11-18. <https://doi.org/10.1200/JCO.2011.35.4639>

Koskinen MJ, Kautio AL, Haanpää ML, Haapasalo HK, Kellokumpu-Lehtinen PL, Saarto T, Hietaharju AJ. 2011. Intraepidermal nerve fibre density in cancer patients receiving adjuvant chemotherapy. *Anticancer Research*. 31(12):4413-4416.

Kilpeläinen TP, Tammela TLJ, Roobol M, Hugosson J, Ciatto S, Nelen V, Moss S, Määttänen L, Auvinen A. 2011. False-positive screening results in the European randomized study of screening for prostate cancer. *EUROPEAN JOURNAL OF CANCER*. 47(18):2698-2705. <https://doi.org/10.1016/j.ejca.2011.06.055>

Haillot O, Fraga A, Maclukiewicz P, Pushkar D, Tammela T, Höfner K, Chantada V, Gagnier P, Morrill B. 2011. The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study. *PROSTATE CANCER AND PROSTATIC DISEASES*. 14(4):302-306. <https://doi.org/10.1038/pcan.2011.13>

Cropp CD, Simpson CL, Wahlfors T, Ha N, George A, Jones MS, Harper U, Ponciano-Jackson D, Green TA, Tammela TLJ, Bailey-Wilson J, Schleutker J. 2011. Genome-wide linkage scan for prostate cancer susceptibility in Finland: Evidence for a novel locus on 2q37.3 and confirmation of signal on 17q21-q22. *International Journal of Cancer*. 129(10):2400-2407. <https://doi.org/10.1002/ijc.25906>

Vihinen PP, Ramadan S, Vuoristo MS, Hernberg M, Tyynelä-Korhonen K, Skyttä T, Koskivuo I, Kellokumpu-Lehtinen PL, Syrjänen K, Pyrhönen S. 2011. Circulating levels of VEGFR-1 and VEGFR-2 in patients with metastatic melanoma treated with chemoimmunotherapy alone or combined with bevacizumab. *MELANOMA RESEARCH*. 21(5):431-437. <https://doi.org/10.1097/CMR.0b013e32834941d3>

Kemppainen KJ, Tammela TLJ, Auvinen A, Murtola TJ. 2011. The association between antihypertensive drug use and incidence of prostate cancer in Finland: A population-based case-control study. *Cancer Causes and Control*. 22(10):1445-1452. <https://doi.org/10.1007/s10552-011-9819-3>

Larjavaara S, Feychting M, Sankila R, Johansen C, Klaeboe L, Schüz J, Auvinen A. 2011. Incidence trends of vestibular schwannomas in Denmark, Finland, Norway and Sweden in 1987-2007. *British Journal of Cancer*. 105(7):1069-1075. <https://doi.org/10.1038/bjc.2011.344>

Mattila H, Schindler M, Isotalo J, Ikonen T, Vihinen M, Oja H, Tammela TLJ, Wahlfors T, Schleutker J. 2011. NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene. *BMC Cancer*. 11. <https://doi.org/10.1186/1471-2407-11-327>

Nurminen R, Wahlfors T, Tammela TLJ, Schleutker J. 2011. Identification of an aggressive prostate cancer predisposing variant at 11q13. *International Journal of Cancer*. 129(3):599-606. <https://doi.org/10.1002/ijc.25754>

Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM. 2011. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. *Cancer Research*. 71(6):2108-2117. <https://doi.org/10.1158/0008-5472.CAN-10-1998>

Latonen L, Moore HM, Bai B, Jäämaa S, Laiho M. 2011. Proteasome inhibitors induce nucleolar aggregation of proteasome target proteins and polyadenylated RNA by altering ubiquitin availability. *Oncogene*. 30(7):790-805. <https://doi.org/10.1038/onc.2010.469>

Schüz J, Elliott P, Auvinen A, Kromhout H, Poulsen AH, Johansen C, Olsen JH, Hillert L, Feychting M, Fremling K, Toledano M, Heinävaara S, Slottje P, Vermeulen R, Ahlbom A. 2011. An international prospective cohort study of mobile phone users and health (Cosmos): Design considerations and enrolment. *CANCER EPIDEMIOLOGY*. 35(1):37-43. <https://doi.org/10.1016/j.canep.2010.08.001>

Schwartzman J, Mongoue-Tchokote S, Gibbs A, Gao L, Corless CL, Jin J, Zarour L, Higano C, True LD, Vessella RL, Wilmot B, Bottomly D, McWeeney SK, Bova SG, Partin AW, Mori M, Alumkal JJ. 2011. A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer. *EPIGENETICS*. 6(10):1248-1256. <https://doi.org/10.4161/epi.6.10.17727>

Azaïs H, Moussaron A, Bach SK, Bassil A, Betrouni N, Frochot C, Collinet P, Mordon S. 2014. FRα: une cible pour la thérapie photodynamique prophylactique des métastases péritonéales ovariennes?. *BULLETIN DU CANCER*. 101(12):1109-1113. <https://doi.org/10.1684/bdc.2014.1977>

Colin P, Estevez JP, Betrouni N, Nevoux P, Puech P, Leroy X, Biserte J, Villers A, Mordon S. 2011. Thérapie photodynamique et carcinomes urothéliaux. *BULLETIN DU CANCER*. 98(7):769-778. <https://doi.org/10.1684/bdc.2011.1389>